Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Acerus Pharmaceuticals
company
About
Acerus Pharmaceuticals Corporation is a Canadian-based specialty pharmaceutical company.
- 1 - 10
Highlights
Details
- Last Funding Type
- Post-IPO Debt
- Last Funding Money Raised
- $2M
- Industries
- Clinical Trials,Medical,Pharmaceutical
- Founded date
- Jan 1, 2008
- Number Of Employee
- 1 - 10
- Operating Status
- Active
Acerus Pharmaceuticals Corporation is a Canadian-based specialty pharmaceutical company focused on the commercialization and development of innovative prescription products that improve patient experience, with a primary focus in the field of men’s health. The Company commercializes its products via its own salesforce in the United States and Canada, and through a global network of licensed distributors in other territories.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$2M
Acerus Pharmaceuticals has raised a total of
$2M
in funding over 2 rounds. Their latest funding was raised on
Apr 26, 2018 from a Post-IPO Debt round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Apr 26, 2018 | Post-IPO Debt | $2M | 1 |
Quantius
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
1
Acerus Pharmaceuticals is funded by 1 investors.
Quantius
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Quantius
|
Yes | Post-IPO Debt |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
